Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06116110 · ClinicalTrials.gov registry record
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
A clinical trial of Non-Hodgkin Lymphoma, sponsored by Miltenyi Biomedicine.
- Recruiting
- Registry status
- 150
- Enrollment target
- 5
- Study locations
NCT06116110 is a study of Non-Hodgkin Lymphoma that is actively recruiting participants, run by Miltenyi Biomedicine. The registered enrollment target is 150 participants, roughly in line with the 150-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target. The trial reports 5 study locations across 5 states.
The verdict
NCT06116110, a study of Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by Miltenyi Biomedicine.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.
Conditions Studied
Interventions
- OTHER Long-term Follow-Up
Study Locations (5)
California
- Stanford University - Stanford
Connecticut
- Yale University - New Haven
Maryland
- University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center - Baltimore
Massachusetts
- Dana Farber Cancer Institute - Boston
Wisconsin
- Froedtert Hospital and the Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-05-15 |
| Est. Completion | 2039-12-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06116110
The ClinicalTrials.gov registry entry for NCT06116110 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 150-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target. The listed sponsor is Miltenyi Biomedicine, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Long-term Follow-Up is the first listed.
NCT06116110 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Connecticut, Maryland.
Frequently Asked Questions
What is clinical trial NCT06116110 about?
NCT06116110 is a clinical study titled "Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU". This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.
What is the current status of trial NCT06116110?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2024-05-15. Estimated completion is 2039-12-01.
What conditions does trial NCT06116110 study?
This clinical trial studies the following conditions: Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT06116110?
The interventions under investigation include: Long-term Follow-Up (OTHER).
Who is sponsoring clinical trial NCT06116110?
This trial is sponsored by Miltenyi Biomedicine, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06116110 being conducted?
This trial has 5 study locations across California, Connecticut, Maryland, Massachusetts, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
RECRUITING · Early Phase 1
-
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.